^
Association details:
| Biomarker: | MDM2 amplification |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | milademetan (RAIN-32) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P6-10-10 Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
Published date:
11/22/2022
Excerpt:
Preclinical data show that the MDM2 inhibitor milademetan has antitumor activity in GATA3-mutant and MDM2-amplified HR+ breast cancers, and support the clinical evaluation of milademetan in these tumors.
